Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: A randomised controlled trial

Carol Angela Howell, Elena Markaryan, Victoria Allgar, Anu Kemppinen, Aleksander Khovanov, Preeti Pandya, Ramesh Arasaradnam*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background Acute intestinal infections are common conditions causing high morbidity and mortality especially in the young and elderly, resulting in a significant burden on health service resources and the economy. Current National Institute for Health and Care Excellence guidance are fluid and nutritional management; however, this does not reduce the duration of diarrhoea and the challenge of treating diarrhoea itself remains. We investigated the efficacy, tolerability and safety of intestinal adsorbent Enterosgel (polymethylsiloxane polyhydrate) compared with standard care in adults with acute diarrhoea. Methods This was a randomised controlled trial enrolling 105 subjects to receive the medical device Enterosgel up to six times daily for up to 8 days with standard care (oral rehydration solution), or standard care alone. The primary endpoint was the duration of diarrhoea (hours) from randomisation to first non-loose stool in the Enterosgel versus control group. Results A total of 51 subjects were randomised into the Enterosgel group and 54 into the control group, after excluding missing data, the data from 43 subjects in each group were analysed. Duration of diarrhoea was significantly shorter in the Enterosgel group at 27 hours versus 39 hours in the control group (HR was 1.74 [95% CI 1.06 to 2.87]) (p=0.03). This yielded a number needed to treat value of 5. Enterosgel was well tolerated and safe with no serious adverse events. One serious diarrhoea-related event resulting in hospitalisation was reported in the control group. Conclusions Enterosgel treatment was associated with a significant reduction in the duration of diarrhoea in adults with patient-reported acute diarrhoea, compared with standard care. These findings support the role of Enterosgel in acute diarrhoea especially in vulnerable groups where rapid resolution of symptoms is required. Reduction in symptom duration could translate to less healthcare costs and socioeconomic burden. Trial registration number ISRCTN20758708.

Original languageEnglish
Article numbere000287
JournalBMJ Open Gastroenterology
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Apr 2019

Bibliographical note

© Author(s) (or their employer(s)) 2019.

Keywords

  • bacterial infection
  • diarrhoea
  • dietary-gastrointestinal infections
  • infectious diarrhoea

Cite this